Striking differences in proconvulsant-induced alterations of seizure threshold in two rat models

NeuroToxicology

Volumn 33, Issue 1, 2012, Pages 127-137

  Bankstahl, Marion ^a,b   Bankstahl, Jens P ^a,b   Bloms Funke, Petra ^c   Löscher, Wolfgang ^a,b  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

Amphetamine; Caffeine; Convulsions; Drug development; Maximal electroshock; Opioids; Pentylenetetrazole

Indexed keywords

AMPHETAMINE; CAFFEINE; CHLORPROMAZINE; OPIATE; PENTETRAZOLE; PHENOBARBITAL; THEOPHYLLINE; TRAMADOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG ACTIVITY; DRUG EFFECT; ELECTRIC SHOCK; ELECTRODE; ELECTROENCEPHALOGRAM; HINDLIMB; HYPERACTIVITY; LOCOMOTION; MALE; MORTALITY; MYOCLONUS; MYOCLONUS SEIZURE; NONHUMAN; PRIORITY JOURNAL; RAT; SEIZURE THRESHOLD; STEREOTYPY;

ANIMALS; ANTICONVULSANTS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHLORPROMAZINE; CONVULSANTS; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ELECTROSHOCK; MALE; PENTYLENETETRAZOLE; PHENOBARBITAL; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; REACTION TIME; SEIZURES; THEOPHYLLINE; TIME FACTORS; TRAMADOL;

MUS; RATTUS; RATTUS NORVEGICUS;

EID: 84855887150     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2011.12.011     Document Type: Article

References (68)

1. Alldredge B.K. Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 1999, 53(Suppl. 2):S68-S70.
2. Alper K., Schwartz K.A., Kolts R.L., Khan A. Seizure incidence in psychopharmacological clinical trials: an analysis of Food and Drug Administration (FDA) summary basis of approval reports. Biol Psychiatry 2007, 62:345-354.
3. Bass A., Kinter L., Williams P. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods 2004, 49:145-151.
4. Bernaskova K., Mares P. Proconvulsant effect of aminophylline on cortical epileptic afterdischarges varies during ontogeny. Epilepsy Res 2000, 39:183-190.
5. Chase P.B., Biros M.H. A retrospective review of the use and safety of droperidol in a large, high-risk, inner-city emergency department patient population. Acad Emerg Med 2002, 9:1402-1410.
6. Chroscinska-Krawczyk M., Jargiello-Baszak M., Walek M., Tylus B., Czuczwar S.J. Caffeine and the anticonvulsant potency of antiepileptic drugs: experimental and clinical data. Pharmacol Rep 2011, 63:12-18.
7. Czuczwar S.J., Ikonomidou C., Kleinrok Z., Turski L., Turski W. Effect of aminophylline on the protective action of common antiepileptic drugs against electroconvulsions in mice. Epilepsia 1986, 27:204-208.
8. Czuczwar S.J., Gasior M., Janusz W., Szczepanik B., Wlodarczyk D., Kleinrok Z. Influence of different methylxanthines on the anticonvulsant action of common antiepileptic drugs in mice. Epilepsia 1990, 31:318-323.
9. Datto C., Rai A.K., Ilivicky H.J., Caroff S.N. Augmentation of seizure induction in electroconvulsive therapy: a clinical reappraisal. J ECT 2002, 18:118-125.
10. Devlin R.J., Henry J.A. Clinical review: major consequences of illicit drug consumption. Crit Care 2008, 12:202.
11. Dunn D.W., Austin J.K., Harezlak J., Ambrosius W.T. ADHD and epilepsy in childhood. Dev Med Child Neurol 2003, 45:50-54.
12. Dunn D.W., Kronenberger W.G. Childhood epilepsy, attention problems, and ADHD: review and practical considerations. Semin Pediatr Neurol 2005, 12:222-228.
13. Frenk H. Pro- and anticonvulsant actions of morphine and the endogenous opioids: involvement and interactions of multiple opiate and non-opiate systems. Brain Res Rev 1983, 6:197-210.
14. Frey H.H., Voits M. Effect of psychotropic agents on a model of absence epilepsy in rats. Neuropharmacology 1991, 30:651-656.
15. Friderichs E., Felgenhauer F., Jongschaap P., Osterloh G. Pharmakologische untersuchungen zur analgesie, abhängigkeits- und toleranzentwicklung von tramadol, einem stark wirksamen analgetikum. Arzneim-Forsch (Drug Res) 1978, 28:122-134.
16. Gasse C., Derby L., Vasilakis-Scaramozza C., Jick H. Incidence of first-time idiopathic seizures in users of tramadol. Pharmacotherapy 2000, 20:629-634.
17. Grond S., Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet 2004, 43:879-923.
18. Haller C.A., Meier K.H., Olson K.R. Seizures reported in association with use of dietary supplements. Clin Toxicol (Phila) 2005, 43:23-30.
19. Hashem A., Frey H.H. The effect of neuroleptics and neuroleptic/analgesic combinations on the sensitivity to seizures in mice. Anaesthesist 1988, 37:631-635.
20. Himmel H.M. Safety pharmacology assessment of central nervous system function in juvenile and adult rats: effects of pharmacological reference compounds. J Pharmacol Toxicol Methods 2008, 58:129-146.
21. Jick H., Derby L.E., Vasilakis C., Fife D. The risk of seizures associated with tramadol. Pharmacotherapy 1998, 18:607-611.
22. Kanner A.M., Gidal B.E. Pharmacodynamic and pharmacokinetic interactions of psychotropic drugs with antiepileptic drugs. Int Rev Neurobiol 2008, 83:397-416.
23. Kelsey M.C., Grossberg G.T. Safety and efficacy of caffeine-augmented ECT in elderly depressives: a retrospective study. J Geriatr Psychiatry Neurol 1995, 8:168-172.
24. Khan L.H., Alderfer R.J., Graham D.J. Seizures reported with tramadol. J Am Med Assoc 1997, 278:1661.
25. Kilian M., Frey H.-H. Central monoamines and convulsive thresholds in mice and rats. Neuropharmacology 1973, 12:681-692.
26. Kimball A.W., Burnett W.T., Doherty D.G. Chemical protection against ionizing radiation. I. Sampling methods for screening compounds in radiation protection studies with mice. Radiat Res 1957, 7:1-12.
27. Kleinrok Z., Czuczwar S., Wojcik A., Przegalinski E. Brain dopamine and seizure susceptibility in mice. Pol J Pharmacol Pharm 1978, 30:513-519.
28. Krupp E., Löscher W. Anticonvulsant drug effects in the direct cortical ramp-stimulation model in rats: comparison with conventional seizure models. J Pharmacol Exp Ther 1998, 285:1137-1149.
29. Kumar S.S., Joshi B., Sharma S.S. CNS safety pharmacology: international guidelines and methods. CRIPS 2007, 8:2-5.
30. Lesani A., Javadi-Paydar M., Khodadad T.K., Asghari-Roodsari A., Shirkhodaei M., Norouzi A., et al. Involvement of the nitric oxide pathway in the anticonvulsant effect of tramadol on pentylenetetrazole-induced seizures in mice. Epilepsy Behav 2010, 19:290-295.
31. Lewis K.S., Han N.H. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm 1997, 54:643-652.
32. Livingston S., Kajdi L., Reid E.M. The use of benzedrine and dexedrine sulfate in the treatment of epilepsy. J Pediatr 1948, 32:490-494.
33. Löscher W., Schmidt D. Which animal models should be used in the search for new antiepileptic drugs. A proposal based on experimental and clinical considerations. Epilepsy Res 1988, 2:145-181.
34. Löscher W., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res 1991, 8:79-94.
35. Löscher W., Hönack D., Fassbender C.P., Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. III. Pentylenetetrazol seizure models. Epilepsy Res 1991, 8:171-189.
36. Löscher W. Pharmacology of glutamate receptor antagonists in the kindling model. Kindling 5 1998, 435-449. Plenum Press, New York. M.E. Corcoran, S.L. Moshé (Eds.).
37. Löscher W. Preclinical assessment of proconvulsant drug activity and its relevance for predicting adverse events in humans. Eur J Pharmacol 2009, 610:1-11.
38. Löscher W., Köhling R. Functional, metabolic, and synaptic changes after seizures as potential targets for antiepileptic therapy. Epilepsy Behav 2010, 19:105-113.
39. Mannino R.A., Wolf H.H. Opiate receptor phenomenon: proconvulsant action of morphine in the mouse. Life Sci 1974, 15:2089-2096.
40. Manocha A., Sharma K.K., Mediratta P.K. Tramadol, a centrally acting opioid: anticonvulsant effect against maximal electroshock seizure in mice. Indian J Physiol Pharmacol 1998, 42:407-411.
41. Manocha A., Sharma K.K., Mediratta P.K. On the mechanism of anticonvulsant effect of tramadol in mice. Pharmacol Biochem Behav 2005, 82:74-81.
42. Markowitz J.C., Brown R.P. Seizures with neuroleptics and antidepressants. Gen Hosp Psychiatry 1987, 9:135-141.
43. Marquardt K.A., Alsop J.A., Albertson T.E. Tramadol exposures reported to statewide poison control system. Ann Pharmacother 2005, 39:1039-1044.
44. Matthiesen T., Wohrmann T., Coogan T.P., Uragg H. The experimental toxicology of tramadol: an overview. Toxicol Lett 1998, 95:63-71.
45. Nehlig A., Daval J.L., Debry G. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res Brain Res Rev 1992, 17:139-170.
46. Ogren S.O., Pakh B. Effects of dopamine D1 and D2 receptor agonists and antagonists on seizures induced by chemoconvulsants in mice. Pharmacol Toxicol 1993, 72:213-220.
47. Osterloh G., Friderichs E., Felgenhauer F., Günzler W.A., Henmi Z., Kitano T., et al. Allgemeine pharmakologische Untersuchungen mit Tramadol, einem stark wirkenden Analgetikum. Arzneim-Forsch (Drug Res) 1978, 28:135-151.
48. Pisani F., Oteri G., Costa C., Di Raimondo G., Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug Saf 2002, 25:91-110.
49. Pollack G.M., Shen D.D. A timed intravenous pentylenetetrazol infusion seizure model for quantitating the anticonvulsant effect of valproic acid in the rat. J Pharmacol Methods 1985, 13:135-146.
50. Porsolt R.D., Lemaire M., Durmuller N., Roux S. New perspectives in CNS safety pharmacology. Fundam Clin Pharmacol 2002, 16:197-207.
51. Potschka H., Friderichs E., Löscher W. Anticonvulsant and proconvulsant effects of tramadol, its enantiomers and its M1 metabolite in the rat kindling model of epilepsy. Br J Pharmacol 2000, 131:203-212.
52. Raffa R.B., Friderichs E., Reimann W., Shank R.P., Codd E.E., Vaught J.L., et al. Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol. J Pharmacol Exp Ther 1993, 267:331-340.
53. Raffa R.B., Stone D.J. Unexceptional seizure potential of tramadol or its enantiomers or metabolites in mice. J Pharmacol Exp Ther 2008, 325:500-506.
54. Rattka M., Brandt C., Bankstahl M., Bröer S., Löscher W. Enhanced susceptibility to the GABA antagonist pentylenetetrazole during the latent period following a pilocarpine-induced status epilepticus in rats. Neuropharmacology 2011, 60:505-512.
55. Rehni A.K., Singh I., Kumar M. Tramadol-induced seizurogenic effect: a possible role of opioid-dependent gamma-aminobutyric acid inhibitory pathway. Basic Clin Pharmacol Toxicol 2008, 103:262-266.
56. Reisine T., Pasternak G. Opioid analgesics and antagonists. Goodman & Gilman's the pharmacological basis of therapeutics 1996, 521-556. McGraw-Hill, New York. 9th ed. J.G. Hardman, L.E. Limbird, P.B. Molinoff, R.W. Ruddon, G.A. Goodman (Eds.).
57. Riffee W.H., Gerald M.C. The effects of chronic administration and withdrawal of (+)-amphetamine on seizure threshold and endogenous catecholamine concentrations and their rates of biosynthesis in mice. Psychopharmacology (Berl) 1977, 51:175-179.
58. Scholl M.L. The diagnosis and treatment of seizures. Pediatr Clin North Am 1962, 9:353-376.
59. Shipton E.A. Tramadol-present and future. Anaesth Intensive Care 2000, 28:363-374.
60. Spear L.P., Brake S.C. Periadolescence: age-dependent behavior and psychopharmacological responsivity in rats. Dev Psychobiol 1983, 16:83-109.
61. Spiller H.A., Gorman S.E., Villalobos D., Benson B.E., Ruskosky D.R., Stancavage M.M., et al. Prospective multicenter evaluation of tramadol exposure. J Toxicol Clin Toxicol 1997, 35:361-364.
62. Stern L., Dannon P.N., Hirschmann S., Schriber S., Amytal D., Dolberg O.T., et al. Aminophylline increases seizure length during electroconvulsive therapy. J ECT 1999, 15:252-257.
63. Strauss H. The effect of mental activity on the incidence of seizures and the electroencephalographic pattern in some epileptics. Psychonom Med 1944, 6:141-145.
64. Swinyard E.A. Electrically induced convulsions. Experimental models of epilepsy-a manual for the laboratory worker 1972, 433-458. Raven Press, New York. D.P. Purpura, J.K. Penry, D. Tower, D.M. Woodbury, R. Walter (Eds.).
65. Taylor S.M. Electroconvulsive therapy, brain-derived neurotrophic factor, and possible neurorestorative benefit of the clinical application of electroconvulsive therapy. J ECT 2008, 24:160-165.
66. Tchekalarova J., Kubova H., Mares P. Effects of postnatal caffeine exposure on seizure susceptibility in developing rats. Brain Res 2007, 1150:32-39.
67. Thundiyil J.G., Kearney T.E., Olson K.R. Evolving epidemiology of drug-induced seizures reported to a Poison Control Center System. J Med Toxicol 2007, 3:15-19.
68. Torta R., Monaco F. Atypical antipsychotics and serotoninergic antidepressants in patients with epilepsy: pharmacodynamic considerations. Epilepsia 2002, 43(Suppl. 2):8-13.